Clinical Trial Update: MK-3475 in Melanoma and NSCLC Patients With Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial update for MK-3475 (pembrolizumab) in melanoma and non-small cell lung cancer patients with brain metastases has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• MK-3475 (pembrolizumab)

Snippet

Sponsor: Yale University | Conditions: Melanoma, Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-03-24